Your browser doesn't support javascript.
loading
Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study.
Salgado, Maria; Gálvez, Cristina; Nijhuis, Monique; Kwon, Mi; Cardozo-Ojeda, E Fabian; Badiola, Jon; Gorman, Matthew J; Huyveneers, Laura E P; Urrea, Victor; Bandera, Alessandra; Jensen, Björn-Erik Ole; Vandekerckhove, Linos; Jurado, Manuel; Raj, Kavita; Schulze Zur Wiesch, Julian; Bailén, Rebeca; Eberhard, Johanna M; Nabergoj, Mitja; Hütter, Gero; Saldaña-Moreno, Raquel; Oldford, Sharon; Barrett, Lisa; Ramirez, Maria Luisa Montes; Garba, Salisu; Gupta, Ravi Kumar; Revollo, Boris; Ferra-Coll, Christelle; Kuball, Jurgen; Alter, Galit; Sáez-Cirión, Asier; Diez-Martin, Jose Luis; Duke, Elizabeth R; Schiffer, Joshua T; Wensing, Annemarie; Martinez-Picado, Javier.
Afiliação
  • Salgado M; IrsiCaixa, Badalona, Spain; Germans Trias i Pujol Research Institute, Badalona, Spain; Centro de Investigación Biomédica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain. Electronic address: msalgado@irsicaixa.es.
  • Gálvez C; IrsiCaixa, Badalona, Spain.
  • Nijhuis M; Translational Virology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands; HIV Pathogenesis Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
  • Kwon M; Department of Hematology, Hospital Universitario Gregorio Marañón, Institute of Health Research Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Cardozo-Ojeda EF; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Xencor, Pasadena, CA, USA.
  • Badiola J; University Hospital Virgen de las Nieves, Granada, Spain.
  • Gorman MJ; Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA, USA; Moderna Therapeutics, Cambridge, MA, USA.
  • Huyveneers LEP; Translational Virology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands.
  • Urrea V; IrsiCaixa, Badalona, Spain.
  • Bandera A; Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
  • Jensen BO; Department of Gastroenterology, Hepatology, and Infectious Diseases, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.
  • Vandekerckhove L; HIV Cure Research Center, Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent University, Ghent, Belgium.
  • Jurado M; University Hospital Virgen de las Nieves, Granada, Spain.
  • Raj K; Kings College Hospital, London, UK.
  • Schulze Zur Wiesch J; Infectious Diseases Unit, Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.
  • Bailén R; Department of Hematology, Hospital Universitario Gregorio Marañón, Institute of Health Research Gregorio Marañón, Madrid, Spain.
  • Eberhard JM; Infectious Diseases Unit, Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany; Helmholtz Institute for One Health, Greifswald, Germany.
  • Nabergoj M; Division of Hematology, Hôpitaux Universitaires de Genève, Geneva, Switzerland; Hematology Service, Institut Central des Hôpitaux, Sion, Switzerland.
  • Hütter G; DKMS Collection Center, Dresden, Germany.
  • Saldaña-Moreno R; Hospital General de Jerez de la Frontera, Cádiz, Spain.
  • Oldford S; Nova Scotia Health, Dalhousie University, Halifax, NS, Canada.
  • Barrett L; Nova Scotia Health, Dalhousie University, Halifax, NS, Canada.
  • Ramirez MLM; Centro de Investigación Biomédica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain; University Hospital La Paz, IdiPAZ, Madrid, Spain.
  • Garba S; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Merck, Rahway, NJ, USA.
  • Gupta RK; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Revollo B; Department of Infectious Diseases, University Hospital Germans Trias i Pujol, Institut Català d'Oncologia, Badalona, Spain.
  • Ferra-Coll C; Department of Hematology, University Hospital Germans Trias i Pujol, Institut Català d'Oncologia, Badalona, Spain; University of Vic-Central University of Catalonia, Vic, Spain.
  • Kuball J; Department of Hematology and Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands.
  • Alter G; Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA, USA; Moderna Therapeutics, Cambridge, MA, USA.
  • Sáez-Cirión A; Viral Reservoirs and Immune Control Unit, Institut Pasteur, Université Paris Cité, Paris, France.
  • Diez-Martin JL; Department of Hematology, Hospital Universitario Gregorio Marañón, Institute of Health Research Gregorio Marañón, Madrid, Spain.
  • Duke ER; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Medicine, Allergy and Infectious Diseases Division, University of Washington, WA, Seattle, USA.
  • Schiffer JT; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Medicine, Allergy and Infectious Diseases Division, University of Washington, WA, Seattle, USA.
  • Wensing A; Translational Virology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands; Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Martinez-Picado J; IrsiCaixa, Badalona, Spain; Germans Trias i Pujol Research Institute, Badalona, Spain; Centro de Investigación Biomédica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain; University of Vic-Central University of Catalonia, Vic, Spain; Catalan Institution for Research a
Lancet HIV ; 11(6): e389-e405, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38816141
ABSTRACT

BACKGROUND:

Allogeneic haematopoietic stem-cell transplantation (allo-HSCT) markedly reduces HIV reservoirs, but the mechanisms by which this occurs are only partly understood. In this study, we aimed to describe the dynamics of virological and immunological markers of HIV persistence after allo-HSCT.

METHODS:

In this prospective observational cohort study, we analysed the viral reservoir and serological dynamics in IciStem cohort participants with HIV who had undergone allo-HSCT and were receiving antiretroviral therapy, ten of whom had received cells from donors with the CCR5Δ32 mutation. Participants from Belgium, Canada, Germany, Italy, the Netherlands, Spain, Switzerland, and the UK were included in the cohort both prospectively and retrospectively between June 1, 2014 and April 30, 2019. In the first 6 months after allo-HSCT, participants had monthly assessments, with annual assessments thereafter, with the protocol tailored to accommodate for the individual health status of each participant. HIV reservoirs were measured in blood and tissues and HIV-specific antibodies were measured in plasma. We used the Wilcoxon signed-rank test to compare data collected before and after allo-HSCT in participants for whom longitudinal data were available. When the paired test was not possible, we used the Mann-Whitney U test. We developed a mathematical model to study the factors influencing HIV reservoir reduction in people with HIV after allo-HSCT.

FINDINGS:

We included 30 people with HIV with haematological malignancies who received a transplant between Sept 1, 2009 and April 30, 2019 and were enrolled within the IciStem cohort and included in this analysis. HIV reservoirs in peripheral blood were reduced immediately after full donor chimerism was achieved, generally accompanied by undetectable HIV-DNA in bone marrow, ileum, lymph nodes, and cerebrospinal fluid, regardless of donor CCR5 genotype. HIV-specific antibody levels and functionality values declined more slowly than direct HIV reservoir values, decaying significantly only months after full donor chimerism. Mathematical modelling suggests that allogeneic immunity mediated by donor cells is the main viral reservoir depletion mechanism after massive reservoir reduction during conditioning chemotherapy before allo-HSCT (half-life of latently infected replication-competent cells decreased from 44 months to 1·5 months).

INTERPRETATION:

Our work provides, for the first time, data on the effects of allo-HSCT in the context of HIV infection. Additionally, we raise the question of which marker can serve as the last reporter of the residual viraemia, postulating that the absence of T-cell immune responses might be a more reliable marker than antibody decline after allo-HSCT.

FUNDING:

amfAR (American Foundation for AIDS Research; ARCHE Program), National Institutes of Health, National Institute of Allergy and Infectious Diseases, and Dutch Aidsfonds.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Transplante de Células-Tronco Hematopoéticas Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet HIV Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Transplante de Células-Tronco Hematopoéticas Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet HIV Ano de publicação: 2024 Tipo de documento: Article